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dialysis and kidney transplantation and to estimate the
regularity of comprehensive conservative management
(CCM) for patients with kidney failure in Europe. This study
uses data from the ERA-EDTA Registry. Additionally, our
study included supplemental data from Armenia, Germany,
Hungary, Ireland, Kosovo, Luxembourg, Malta, Moldova,
Montenegro, Slovenia and additional data from Israel, Italy,
Slovakia using other information sources. Through an online
survey, responding nephrologists estimated the frequency
of CCM (i.e. planned holistic care instead of kidney
replacement therapy) in 33 countries. In 2016, the overall
incidence of replacement therapy for kidney failure was 132
per million population (pmp), varying from 29 (Ukraine) to
251 pmp (Greece). On 31 December 2016, the overall
prevalence of kidney replacement therapy was 985 pmp,
ranging from 188 (Ukraine) to 1906 pmp (Portugal). The
prevalence of peritoneal dialysis (114 pmp) and home
hemodialysis (28 pmp) was highest in Cyprus and Denmark
respectively. The kidney transplantation rate was nearly
zero in some countries and highest in Spain (64 pmp). In 28
countries with five or more responding nephrologists, the
median percentage of candidates for kidney replacement
therapy who were offered CCM in 2018 varied between
none (Slovakia and Slovenia) and 20% (Finland) whereas the
median prevalence of CCM varied between none (Slovenia)
and 15% (Hungary). Thus, the substantial differences across
Europe in the frequency of kidney replacement therapy and
CCM indicate the need for improvement in access to various
treatment options for patients with kidney failure.Kidney International (2021) 100, 182–195; https://doi.org/10.1016/
j.kint.2020.12.010
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E ach year, the European Renal Association–EuropeanDialysis and Transplant Association (ERA-EDTA) Regis-try reports on the frequency and outcomes of dialysis
and kidney transplantation (KTx) in Europe.1,2 This report
is based on data from national and regional renal registries
in Europe and several countries bordering the Mediterranean
Sea. However, not all European countries have a renal registry,
and, hence, the ERA-EDTA Registry annual report cannot
provide a complete overview of kidney replacement therapy
(KRT) in Europe.
Furthermore, comprehensive conservative management
(CCM) has become an alternative to KRT for patients with
end-stage kidney disease (ESKD), in particular for those whoKidney International (2021) 100, 182–195are older, those who have multiple comorbidities, and those
who have an unfavorable prognosis.3 Up to now, little is
known about the frequency of CCM in patients with ESKD in
individual European countries.4,5
In this study, we therefore aimed to determine, more
extensively than before, the frequency of dialysis and KTx
in Europe, by using ERA-EDTA Registry data supplemented
by data from other sources. In addition, we aimed to es-
timate the frequency of CCM for patients with ESKD in
individual European countries based on an online survey
among nephrologists. An added value of this study is that
now, for the first time, the proportional relationship of all
therapeutic options in all European countries can be
estimated.
RESULTS
Figure 1 shows a map of Europe with the incidence of KRTon
day 1 (Figure 1a), prevalence of KRT (Figure 1b), KTx rate
(Figure 1c), mean estimated percentage of patients who were
offered CCM (Figure 1d), and mean estimated prevalence of
CCM (Figure 1e) in all participating countries.
Incidence of KRT
In 2016, 97,996 patients in 39 countries commenced KRT for
ESKD. Figure 2a demonstrates the incidence of KRT by treat-
ment modality, which was highest in Greece (251 per million
population [pmp]), Czech Republic (243 pmp), and Portugal
(236 pmp), whereas it was lowest in Ukraine (29 pmp), Russia
(59 pmp), and Belarus (62 pmp). For Czech Republic, Poland,
Russia, Tunisia (Sfax region), and Slovakia, we were unable to
obtain data on preemptive KTx and therefore we used the
incidence of dialysis instead. The highest incidence of pre-
emptive KTx was reported by the Netherlands (17 pmp),
Turkey (15 pmp), and Norway (12 pmp).
Figure 2b displays the incidence of KRT by treatment
modality on day 91. The incidence of hemodialysis was
highest in Greece (208 pmp), Portugal (199 pmp), and Israel
(157 pmp), whereas for peritoneal dialysis (PD), the inci-
dence was highest in Cyprus (41 pmp), Sweden (38 pmp),
and Denmark (37 pmp).
Prevalence of KRT
On 31 December 2016, 690,173 patients in 45 countries
received KRT for ESKD. Figure 3 shows the prevalence of
KRT by treatment modality. Portugal had the highest preva-
lence of KRT (1906 pmp), followed by Cyprus (1575 pmp)
and Belgium (1286 pmp).
The prevalence of center hemodialysis was highest in
Portugal (1143 pmp), Greece (979 pmp), and Romania (887
pmp), and that of home hemodialysis (HHD) was highest in
Denmark (28 pmp), Finland (25 pmp), and the United183
Figure 1 | (a) Incidence of kidney replacement therapy for end-stage kidney disease per million population (pmp) on day 1 in 2016.
*Countries with incidence data on dialysis patients only (Czech Republic, Poland, Russia, Slovakia, and Tunisia [Sfax region]). **Country with
incidence data on dialysis and preemptive deceased donor kidney transplant patients only (Germany). (b) Prevalence of kidney (continued)
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Figure 2 | (a) Incidence of kidney replacement therapy (KRT) for end-stage kidney disease (ESKD) per million population by
treatment modality on day 1 in 2016. For corresponding numbers and footnotes, see Supplementary Table S1A. (b) Incidence of KRT for
ESKD per million population by treatment modality on day 91 in 2016. For corresponding numbers and footnotes, see Supplementary
Table S1B. HD, hemodialysis; KTx, kidney transplantation; PD, peritoneal dialysis.
VS Stel et al.: Treatments for end-stage kidney disease in Europe c l i n i ca l i nves t iga t ionKingdom (20 pmp). In many countries, HHD was not re-
ported or did not exist. The prevalence of PD was highest in
Cyprus (114 pmp), Denmark (97 pmp), and Sweden (90
pmp). The prevalence of patients with a functioning kidney
transplant was highest in Cyprus (817 pmp), Portugal (693
pmp), and Spain (672 pmp). It was lowest in Ukraine (27
pmp), Serbia (52 pmp), and Armenia (estimated 58 pmp).
Kidney transplantation
In 2016, 26,008 KTx procedures were performed in 44 countries.
Figure 4 depicts the number of KTx procedures performed by
country, demonstrating the highest KTx rates in Spain (64 pmp),
the Netherlands (59 pmp), and France (54 pmp). Notably, in
Spain, the vast majority of transplants were from deceased do-
nors (57 pmp), whereas in the Netherlands, a small majority of
transplants were from living donors (33 pmp). The lowest
number of KTx procedures was performed in Montenegro,=
Figure 1 | (continued) replacement therapy for end-stage kidney diseas
dialysis patients only (Kosovo). (c) Kidney transplantations performed pm
the clinic who were offered comprehensive conservative management in
(e) Proportion of patients with end-stage kidney disease in the clinic wh
countries with at least 5 survey respondents are included.
Kidney International (2021) 100, 182–195North Macedonia, and Ukraine (all 3 pmp) and Armenia (2
pmp), whereas none was performed in Luxembourg.
Comprehensive conservative management
Under the umbrella of the European Union “The Effect of
Differing Kidney Disease Treatment Modalities and Organ
Donation and Transplantation Practices on Health Expendi-
ture and Patient Outcomes” (EDITH) Nephrologist survey,
587 nephrologists from 33 countries estimated the frequency
of CCM (i.e., planned holistic care instead of KRT)
(Supplementary Table S4).
Figure 5a and b shows the estimated median per-
centages of patients who were offered CCM and the
prevalence of CCM in 2018 for countries with at least 5
respondents on the survey. In the remaining 28 coun-
tries, the estimated percentage of ESKD patients who
were offered CCM varied from 0.0% (Slovakia ande pmp on 31 December 2016. *Country with prevalence data on
p in 2016. (d) Proportion of patients with end-stage kidney disease in
2018. Only countries with at least 5 survey respondents are included.
o received comprehensive conservative management in 2018. Only
185
Figure 3 | Prevalence of kidney replacement therapy for end-stage kidney disease per million population by treatment modality on
31 December 2016. For corresponding numbers and footnotes, see Supplementary Table S2. HD, hemodialysis; KTx, kidney transplantation;
PD, peritoneal dialysis.
c l i n i ca l i nves t iga t i on VS Stel et al.: Treatments for end-stage kidney disease in EuropeSlovenia) to 20.0% (Finland). The estimated prevalence
of CCM ranged between 0.0% (Slovenia) and 15.0%
(Hungary).
Summary statistics
In 2016, the overall incidence of KRT in Europe was 132 pmp,
reflecting that in this year, 1 in 7584 Europeans (0.013%) started
KRT (Table 1). The overall prevalence of KRT was 985 pmp,
reflecting that 1 in 1016 Europeans (0.098%) was treated with KRT.
The overall number of KTx procedures performed was 38 pmp.
Supplementary tables
Supplementary Table S5 provides general population data by
country. Supplementary Tables S1–S4 present all values cor-
responding to Figures 2–5, respectively. Supplementary
Tables S1 and S2 show country-specific data on center he-
modialysis, HHD, PD, as well as living and deceased donor
KTx procedures separately. Supplementary Table S4 shows
data of all countries on both the estimated mean percentage186(SD) and median percentage (interquartile range) of patients
who were offered CCM and on the prevalence of CCM.DISCUSSION
The current study presents the most extensive data on the fre-
quency of KRT for ESKD in Europe so far. In addition to ERA-
EDTA Registry data, data on 10 more countries (Armenia,
Germany, Hungary, Ireland, Kosovo, Luxembourg, Malta, Mol-
dova, Montenegro, and Slovenia) were included. This implies
that, with the exception of some small countries (Andorra,
Liechtenstein, Monaco, San Marino, and Vatican City), all na-
tions in Europe were represented. Moreover, this study estimated
the frequency of CCM for ESKD in 33 European countries.
Incidence of KRT
Our findings show that the overall incidence of KRT in Europe
was 132 pmp in 2016. This is substantially lower than the
incidence of KRT in the United States (378 pmp), Japan (296Kidney International (2021) 100, 182–195
Figure 4 | Kidney transplantations performed per million population in 2016, by donor source. For corresponding numbers and
footnotes, see Supplementary Table S3.
VS Stel et al.: Treatments for end-stage kidney disease in Europe c l i n i ca l i nves t iga t ionpmp), and Canada (200 pmp) but higher than the incidence in
Australia and New Zealand (117 and 119 pmp, respectively).6
Across the world, the KRT incidence has been reported to
vary nearly 22-fold, ranging from 22 pmp in South Africa to
493 pmp in Taiwan.6 Of note, this difference may even be
higher as for some countries without KRT data, the incidence
may be low or KRTmay not exist at all. Our results show that in
Europe, the KRT incidence varied nearly 9-fold, ranging from
29 pmp in Ukraine to 251 pmp in Greece. According to our
results, the vast majority of European patients started on he-
modialysis, whereas only about 4% underwent preemptive KTx,
which is slightly higher than in the United States (2.8%).6 Trend
analysis of data from 14 countries from the ERA-EDTA Registry
database suggests a slight increase in the crude incidence of KRT
in Europe over the period 2012 to 2016.7Kidney International (2021) 100, 182–195Several factors may contribute to the international differ-
ences in KRT incidence. First, they may be due to variation in
the prevalence of chronic kidney disease (CKD) stages 3 to 5 in
the general population,8 which, in turn, may be explained by
differences in the prevalence of risk factors for CKD, such as
diabetes mellitus.9 Second, international differences may exist
in the progression of CKD and in mortality of patients with
CKD (e.g., because of differences in genetic predisposition or
primary and secondary preventive measures).10 Third, the
access to KRT may vary because of differences in patient se-
lection, the timing of KRT initiation, and availability of ESKD
treatment options (e.g., a higher incidence of CCM may result
in a lower incidence of KRT).11–13 Also, macroeconomic fac-
tors, such as health care expenditure, are believed to have a
strong influence on the access to KRT.11,14187
Figure 5 | (a) Proportion of patients with end-stage kidney disease in the clinic who got offered comprehensive conservative
management in 2018. The data are presented as medians. Only countries with at least 5 survey respondents are included. For corresponding
numbers and footnotes, see Supplementary Table S4. (b) Proportion of patients with end-stage kidney disease in the clinic who received
comprehensive conservative management in 2018. The data are presented as medians. Only countries with at least 5 survey respondents are
included. For corresponding numbers and footnotes, see Supplementary Table S4.
Table 1 | Summary statistics of the incidence and prevalence
of KRT for ESKD in European countries by treatment modality
and the number of performed KTx procedures by donor
source, pmp, in 2016
Variable KRT HD PD KTx LD KTx DD KTx
Incidence pmp on day 1 132 109 17 5
Incidence pmp on day 91 122 99 17 5
Prevalence pmp on 31
December 2016
985 502 52 430
No. of performed kidney
transplants pmp
38 8 30
DD, deceased donor; ESKD, end-stage kidney disease; HD, hemodialysis; KRT, kidney
replacement therapy; KTx, kidney transplantation; LD, living donor; PD, peritoneal
dialysis; pmp, per million population.
Categories may not add up because of missing values or rounding off. The summary
statistics are based on data from the following countries: Albania, Austria, Belarus,
Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Denmark, Estonia, Finland, France,
Georgia, Greece, Iceland, Italy, Latvia, Lithuania, the Netherlands, North Macedonia,
Norway, Portugal, Romania, Serbia, Spain, Sweden, Switzerland, Ukraine, and United
Kingdom.
c l i n i ca l i nves t iga t i on VS Stel et al.: Treatments for end-stage kidney disease in EuropePrevalence of KRT
In 2016, the overall prevalence of KRT in Europe was 985
pmp. This is much lower than the reported prevalence in
Japan (2599 pmp), the United States (2196 pmp), and Canada
(1346 pmp) and similar to the prevalence in Australia and
New Zealand (988 and 966 pmp, respectively).6 Across the
world, KRT prevalence varied nearly 29-fold, ranging from
117 pmp in Bangladesh to 3392 pmp in Taiwan.6 Again, it is
noteworthy that for several countries, the KRT prevalence is
not known or KRT may not exist. Our findings show that in
Europe, the KRT prevalence varied 10-fold, ranging from 188
pmp in Ukraine to 1906 pmp in Portugal in 2016. More than
half of all patients (51% in Europe and 70% in the United
States) were on dialysis, whereas in Taiwan and Japan, almost
all patients were on dialysis and KTx rates were lower.6
Nonetheless, also in some European countries with a high
KRT prevalence (e.g., Germany, Greece, and Romania), the
vast majority of patients were on dialysis while the KTx rates
were low. According to data from the ERA-EDTA Registry,
there has been a continuous increase in the prevalence of KRT
in Europe between 2012 and 2016.7
Dialysis modalities
In-center hemodialysis is by far the most commonly used
dialysis modality in Europe, despite several studies demon-
strating minimal differences in patient survival15 and quality
of life16,17 between in-center hemodialysis and PD, and PD
could be a cost-saving therapy compared with in-center he-
modialysis in most countries.18,19 Access to PD is limited,
particularly in some central and eastern European countries.5
This may partly be due to large hemodialysis providers188running dialysis units in these countries as well as to the high
cumulative costs of PD solutions compared with the costs of
personnel. The number of patients using HHD in Europe is
small, and this treatment does not even exist in many coun-
tries. Worldwide, HHD was most prevalent in New Zealand
(17% of dialysis patients).6 Interestingly, in only 3 areas in the
world (Hong Kong, Jalisco [Mexico], and Guatemala), >50%
of the dialysis population is on HHD or PD.6
Kidney transplantation
KTx is associated with superior survival and quality of life and
lower costs compared with dialysis.18,20–22 However, patientsKidney International (2021) 100, 182–195
VS Stel et al.: Treatments for end-stage kidney disease in Europe c l i n i ca l i nves t iga t ionwith ESKD who are suitable for KTx may not always receive a
kidney because of barriers, such as lack of donors, patients’ or
nephrologists’ attitudes or beliefs, legislative issues, and
financial barriers.23–26 On the other hand, a significant share
of patients with ESKD may be unsuitable for KTx, due to, for
example, medical contraindications. In such cases, dialysis or
CCM may be more appropriate.
A great variation in KTx rates exists between the European
countries, ranging from almost zero in some countries to a
maximum of 64 pmp in Spain. Within Europe, the vast ma-
jority of kidneys are obtained from deceased donors (almost
80%), whereas worldwide this is somewhat lower (63.5%).27 Of
note, in Jalisco, a region in Mexico with the highest KTx rate
(79 pmp) in the world, >80% of the kidneys come from living
donors.6 Interestingly, the ratio of living donor versus deceased
donor kidneys varied markedly across the European countries.
In Spain, the vast majority of kidneys are from deceased donors,
largely because of the implementation of various measures, such
as an earlier referral of possible donors to the transplant co-
ordination team, training courses for professionals, and mea-
sures to minimize inappropriate discard of donor organs.28 By
contrast, in the Netherlands, another country with a high KTx
rate, more than half of kidneys are from living donors. This may
be attributable to several initiatives, such as home-based edu-
cation about living donation, a nationwide collaboration in
paired exchange of living donor kidneys, and a financial
compensation of sick leave from work for the living donor.29
The opt-out organ donation system, in which everyone is
considered a potential donor unless they state their wish not to
donate organs at the time of death, is often considered as
another means to expand the deceased donor pool. However, a
recent publication did not find a difference in the total and
deceased donor KTx rates between countries with opt-in and
opt-out systems.30
Comprehensive conservative management
So far, little information exists on the frequency of CCM in
individual European countries. In the United Kingdom, CCM
was available in almost all renal units in 2013, with a large
variation in the number of patients between the centers.31 In a
Spanish single-center study from the same time period, CCM
was provided to 39% of ESKD patients.32 In 2009, researchers
from the ERA-EDTA Registry found that, in 11 European
countries, CCM was provided to 15% of the ESKD patients
on average.4 In the current analysis, we repeated part of this
previous ERA-EDTA Registry study using the EDITH
Nephrologist survey, but covering more countries and
allowing comparison per individual country. In line with the
Global Kidney Health Atlas, we found that CCM was prac-
ticed in both eastern and western Europe.5 Our findings
suggest large international differences in the frequency of
CCM, with several counties having an estimated prevalence of
CCM of <5% (Belarus, North Macedonia, Serbia, and
Slovenia) and others having an estimated prevalence of CCM
of >10% (Austria and Hungary). Apart from reporting bias
(see below), such international differences may be caused byKidney International (2021) 100, 182–195variation in educational efforts targeting patients, primary
care physicians, and the nephrology community. These efforts
are needed to raise awareness about CCM as an appropriate
treatment option for patients who are not expected to benefit
from KRT. Education needs to be supported financially, and
the lack of the financial support could also explain the limited
implementation of CCM in different countries. In addition,
nephrologists may experience barriers when offering CCM,
such as moral concerns and discomfort about initiating what
is expected to be a difficult discussion with the patient and
family.33
Strengths and limitations
The main strengths of this study are the virtually full coverage
of Europe and the provision of detailed information on the
frequency of KRT, including center hemodialysis, HHD, PD,
and KTx from living and deceased donors separately, as well
as on CCM.
This study also has several limitations. First, some data
(e.g., on the type of kidney donor) were unavailable for
some countries. Second, for certain countries, the frequency
of KRT modalities was estimated or derived from personal
communication or scientific papers. Furthermore, we esti-
mated the prevalence of patients living with a functioning
kidney transplant for 5 countries with unknown prevalence.
The frequency of CCM was estimated by several nephrol-
ogists per country based on a survey, and the sample may
not be representative to all nephrologists in the country.
We did not directly contact potential respondents and
therefore we do not know which persons received the
survey and whether they responded or not. Consequently,
we were not able to calculate a response rate or compare
the characteristics of responders with those of non-
responders. Third, although we provided the definition of
CCM to the respondents, we cannot rule out that ne-
phrologists may have interpreted CCM as choice-restricted
conservative care, resulting from limited resources.34 Defi-
nitions of other treatments may differ between countries
(e.g., center hemodialysis can include self-care hemodialy-
sis), and some treatments may not be registered adequately
(e.g., HHD). Of note, the number of individuals with
unrecognized ESKD may vary across countries.
Conclusion
This extensive overview demonstrates large differences in the
frequency of dialysis and KTx across the European countries.
In addition, for the first time, it is shown that the frequency of
CCM also differs markedly between countries.
Our findings may prove useful for identifying potential
areas for improvement in the access to the various treatment
options for patients with ESKD. These areas could include
stimulating home dialysis compared with in-center hemodi-
alysis (e.g., through more balanced and equitable reim-
bursement of patients and dialysis modalities and educating
patients and health care professionals), increasing access to
KTx (e.g., through organized donor coordination,189
Table 2 | Sources used to obtain information on the frequency of dialysis, kidney transplantation, and comprehensive
conservative management for patients with ESKD in different European countries
Country
Population
data Incidence of KRT on day 1
Incidence
of KRT on






















































































































Germany Eurostat GBA report: reference below table
(personal communication with
Wolfgang Weber from MNC, Medical
Netcare GmbH, 2019) (dialysis)















Hungary Eurostat USRDSb USRDS GODT website EDITH
Nephrologist
survey



















ERA-EDTA Registryc GODT website EDITH
Nephrologist
survey
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EDITH, “The Effect of Differing Kidney Disease Treatment Modalities and Organ Donation and Transplantation Practices on Health Expenditure and Patient Outcomes”; ERA-
EDTA, European Renal Association–European Dialysis and Transplant Association; ESKD, end-stage kidney disease; GODT, Global Observatory on Donation and Trans-
plantation; KRT, kidney replacement therapy; USRDS, US Renal Data System.
No data were available for the following countries in Europe: Andorra, Liechtenstein, Monaco, San Marino, and Vatican City. When cells are left empty, the data were un-
available. Gemeinsamer Bundesausschuss report: Potthoff F, Münscher C, Berendes A, Weber W. Jahresbericht 2016 zur Qualität in der Dialyse. Münster, Germany: MNC, Medical
Netcare GmbH; 2017. Available at: https://www.g-ba.de/richtlinien/45/. GODT website: http://www.transplant-observatory.org/data-charts-and-tables/. For other footnotes, see
Supplementary Tables S1A, S1B, S2, S3, and S4.
aPrevalence of kidney transplantation was estimated with kidney transplantation rate (formula based on data from countries with known kidney transplantation prevalence
and kidney transplantation rate).
bOnly KRT incidence available.
cIncidence and prevalence are based on data from 6 of 20 Italian regions.
dThis designation is without prejudice to position on status and is in line with United Nations Security Council Resolutions 1244/99 and the International Court of Justice
Opinion on the Kosovo declaration of independence.
eIncidence and prevalence are based on data from 14 of 19 Spanish regions.
c l i n i ca l i nves t iga t i on VS Stel et al.: Treatments for end-stage kidney disease in Europeoptimization of the donation processes, and provision of
appropriate legal, financial, and policy frameworks),35 and
increasing availability of CCM (e.g., through educating pa-
tients and health care professionals and better aligned reim-
bursement for dialysis and CCM). Countries can learn from
each other how to increase these treatment options. It is
desirable to set up structural data collections on the frequency
of CCM as these are currently missing, and on the frequency
of KRT in countries where such data collections do not exist.
The existing national and regional renal registries are valuable
in assessing the frequency of KRT and may therefore play an
important role in reducing European inequalities in kidney
care.
METHODS
Table 2 provides an overview of all sources used to determine the
frequency of dialysis, KTx, and CCM as treatment for patients with
ESKD by country. Countries considered to be geographically in both
Europe and Asia (Armenia, Georgia, Russia, and Turkey) were also
included, as well as Israel and Tunisia, because they also provided
2016 data to the ERA-EDTA Registry.
Data collection on KRT
ERA-EDTA Registry data. National and regional renal registries
that submitted individual patient data or aggregated data on the year
2016 to the ERA-EDTA Registry were included. The details of methods
of data collection and data processing have been described elsewhere.1192All renal registries contributing individual patient data to the
ERA-EDTA Registry followed national legislation with regard to
ethics committee approval and patient informed consent.
Other sources. For countries not providing data to the ERA-
EDTA Registry, other sources were used to determine the fre-
quency of KRT. These sources included insurance data (Germany),37
the chapter on international comparisons in the US Renal Data
System report (Hungary and Israel),6 personal communication
(Cyprus and Ireland), Newsletter Transplant (Armenia, Malta, and
Moldova),38 the Eurotransplant annual report (Germany,
Luxembourg, and Slovenia),39 a scientific article on the results of a
survey among nephrologists (Kosovo, Montenegro, and Slovenia),40
and a scientific article on the results of a survey among representa-
tives of eastern European countries of the International Society of
Nephrology Regional Board (Montenegro) (Table 2).36 For some
countries, we used estimates on the incidence of dialysis (Germany),
the incidence of KRT (Hungary), and the prevalence of dialysis
(Armenia, Malta, and Moldova).
The Global Observatory on Donation and Transplantation data27
were used to obtain the number of KTx procedures performed in
Armenia, Germany, Hungary, Ireland, Italy (entire country), Malta,
Montenegro, Moldova, and Slovenia. Data from Luxembourg were
obtained from the Eurotransplant annual report.39
Definitions of the frequency of KRT. The modality-specific
incidence on day 1 was defined as the number of patients starting
on each modality in 2016 and expressed as pmp. The modality-
specific incidence, pmp, was also examined on day 91 after KRT
initiation, because some patients receive hemodialysis for a shortKidney International (2021) 100, 182–195
VS Stel et al.: Treatments for end-stage kidney disease in Europe c l i n i ca l i nves t iga t ionperiod while preparations are made for PD. The modality-specific
prevalence was defined as the number of patients on each modal-
ity on 31 December 2016. Both the prevalence and the number of
transplants performed in 2016 were also expressed as pmp. Some
exceptions to these rules are described in the footnotes of the tables
and figures.
As general population data, we used the midyear population of
2016, as provided by Eurostat,41 for countries sending individual
patient data to the ERA-EDTA Registry. Exceptions to this approach
were Austria, Bosnia and Herzegovina, the Spanish regions, and the
United Kingdom, which provided their own population data. For
countries providing aggregated data to the ERA-EDTA Registry, we
used population data as provided by the national registry. For
countries not providing data to the ERA-EDTA Registry in 2016, we
used the midyear population of 2016, as provided by Eurostat.Data collection on CCM
As part of the EDITH project,13 the ERA-EDTA Registry adminis-
tered an online EDITH survey among European nephrologists and
kidney transplant surgeons. The survey was publicly accessible from
March 14, 2019 until May 19, 2019. The survey received a waiver
from the Medical Ethical Review Committee of the Amsterdam
University Medical Centers, location Academic Medical Center
(W18_279#18.323). Included in the final analysis were results from
respondents from countries for which additional ethical approval
was either not needed or received before the start of the survey.
Because of lack of ethical approval, Albania, Iceland, Lithuania,
Luxembourg, Montenegro, and Portugal did not participate in the
survey, and we received no responses from Bosnia and Herzegovina.
All respondents provided online informed consent before
completing the survey.
The 2 questions about CCM were completed by nephrologists
only. The definition of CCM in the survey was based on both the
Kidney Disease: Improving Global Outcomes guideline42 and the
executive summary of a Kidney Disease: Improving Global Out-
comes Controversies Conference on Supportive Care in CKD34:
“CCM is defined as planned holistic patient-centered care for pa-
tients with stage 5 CKD who require KRT but do not receive this
treatment. CCM includes interventions to delay the progression of
kidney disease, shared decision-making, active symptom manage-
ment, detailed communications including advanced care planning,
psychological support, social and family support and cultural and
spiritual domains of care.” CCM does not include “choice-restricted
conservative care” for patients in whom resource constraints prevent
or limit access to KRT. The first question asked for an estimation of
the percentage of patients in the clinic who were offered CCM
instead of KRT in 2018, in case the patient had a level of kidney
function for which the nephrologist would normally start KRT (of
note, this is not equal to the incidence of CCM as patients may not
accept the offer). The second question concerned an estimation of
the percentage of ESKD patients in the clinic who received CCM
(further indicated as prevalence of CCM). Of note, the latter per-
centages may be higher than the first, as patients receiving CCM may
survive >1 year with CCM.
Analyses
Summary statistics on the frequency of KRT in Europe were calcu-
lated for all participating countries providing data on the incidence
and prevalence of hemodialysis, PD, and KTx as well as data on KTx
rates (i.e., the number of KTx procedures performed pmp). As IsraelKidney International (2021) 100, 182–195and Tunisia are not part of Europe, these countries were not included
in the summary statistics. The summary statistics were therefore
based on 28 countries representing 44.7% of the population of all
countries (minus Israel and Tunisia) included in this study.
For some countries (Armenia, Germany, Malta, Moldova, and
Slovenia), we did not have information on the prevalence of patients
with a functioning kidney graft and therefore we estimated the
prevalence for these countries. To this end, using data from 36 Eu-
ropean countries, we developed a regression formula describing the
relationship between KTx rates and the prevalence of patients with a
functioning kidney transplant in 2016 (Supplementary Figure S1;
R2 ¼ 0.78).
For the analyses on the frequency of CCM in each country, we
calculated the median and interquartile range (presented in main
article as distributions were skewed) as well as the mean and SD of
the percentages of CCM. In the figures, we present the results of
countries with at least 5 survey respondents. The supplement in-
cludes the results of all countries. The frequencies of KRT and CCM
are presented as unadjusted results. The analyses were performed
using SAS software version 9.4.43DISCLOSURE
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